OTHER INFORMATION
−Removed: (a) Entry into a Material Definitive Agreement
−Removed: On May 6, 2024, we amended our facility lease agreement (the lease as amended, the “Amended Lease”) with BMR-Pacific Research Center LP to lease 60,575 rentable square feet of office and laboratory space located within the Newark, California facility the Company has occupied since 2017.
−Removed: The term of the Amended Lease commences on July 1, 2024 (or such later date when tenant improvements in newly leased office space within the facility are substantially
−Removed: The term of the Amended Lease is 65 months.
−Removed: The initial monthly base rent under the Amended Lease is $3.53 per square foot.
−Removed: Base rent will increase 3.5% annually.
−Removed: The Amended Lease provides for an agreed-upon period of rent abatement.
−Removed: We are responsible for our proportional share of operating expenses and tax obligations throughout the lease term.
−Removed: No additional security deposit was required pursuant to the Amended Lease.
−Removed: The foregoing description of the Amended Lease does not purport to be complete and is qualified in its entirety by reference to the Amended Lease, a copy of which will be filed as an exhibit to the Company’s quarterly report on Form 10-Q for the period ending June 30, 2024.
(c) Trading Plans
−Removed: During the fiscal quarter ended March 31, 2024, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case as defined in Item 408(a) of Regulation S-K.
+Added: On April 22, 2024 , Dinesh V.
+Added: Patel , our Chief Executive Officer and member of our Board , adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 300,000 shares of the Company’s common stock through July 31, 2025, or such earlier date when all transactions under the trading plan are completed, subject to certain conditions.
+Added: During the fiscal quarter ended June 30, 2024, no other director or Section 16 officer adopted or terminated any Rule
+Added: 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (in each case as defined in Item 408(a) of Regulation S-K).
EXHIBIT INDEX
2 unchanged sentences
Amended and Restated Certificate of Incorporation
+Added: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Protagonist Therapeutics, Inc.
Amended and Restated Bylaws
−Removed: License and Collaboration Agreement by and between Protagonist Therapeutics, Inc.
−Removed: and Takeda Pharmaceuticals USA, Inc.
−Removed: dated January 31, 2024
+Added: Third Amendment to Lease dated March 6, 2017 by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord, dated May 6, 2024
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
14 unchanged sentences
PROTAGONIST THERAPEUTICS, INC.
+Added: August 6, 2024
/s/ Dinesh V.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 6, 2024
Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.